For the past decade, the number of molecular targets for approved drugs has been debated. In this article and the accompanying poster, Overington and colleagues provide a comprehensive survey of current drug targets and a wealth of associated information on the characteristics of target families and the drugs that modulate them.
- John P. Overington
- Bissan Al-Lazikani
- Andrew L. Hopkins